Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma

Lenvatinib, a multi-kinase inhibitor, serves a crucial role in the treatment of unresectable hepatocellular carcinoma (HCC). However, >50% of patients receiving lenvatinib therapy experience tumor growth or metastasis within 1 year, highlighting the need to address acquired resistance as a critic...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Masamitsu, Araki, Takuya, Yashima, Hideaki, Nagamine, Ayumu, Nagano, Daisuke, Yamamoto, Koujirou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654551/
https://www.ncbi.nlm.nih.gov/pubmed/38020292
http://dx.doi.org/10.3892/ol.2023.14116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654551/
https://www.ncbi.nlm.nih.gov/pubmed/38020292
http://dx.doi.org/10.3892/ol.2023.14116

Ejemplares similares